tiprankstipranks
Advertisement
Advertisement
Edward Nash Initiates Buy on Sagimet, Citing De-Risked Late-Stage Acne Program and Significant U.S. Market Opportunity
PremiumRatingsEdward Nash Initiates Buy on Sagimet, Citing De-Risked Late-Stage Acne Program and Significant U.S. Market Opportunity
15d ago
Sagimet Highlights Q2 Results and Dermatology Focus Shift
Premium
Company Announcements
Sagimet Highlights Q2 Results and Dermatology Focus Shift
16d ago
Sagimet Biosciences reports Q2 EPS (26c), consensus (27c)
Premium
The Fly
Sagimet Biosciences reports Q2 EPS (26c), consensus (27c)
16d ago
Sagimet: Buy Rating Reiterated as Denifanstat Advances and $28 Price Target Remains Unchanged
PremiumRatingsSagimet: Buy Rating Reiterated as Denifanstat Advances and $28 Price Target Remains Unchanged
2M ago
Sagimet Biosciences Announces Board Changes and Director Elections
Premium
Company Announcements
Sagimet Biosciences Announces Board Changes and Director Elections
3M ago
Sagimet Biosciences Grants New Performance-Based Executive Equity Awards
Premium
Company Announcements
Sagimet Biosciences Grants New Performance-Based Executive Equity Awards
3M ago
Sagimet Maintained at Buy as Strong Cash Runway and Advancing Acne Franchise Support Unchanged $28 Price Target
PremiumRatingsSagimet Maintained at Buy as Strong Cash Runway and Advancing Acne Franchise Support Unchanged $28 Price Target
4M ago
Sagimet Biosciences reports Q1 EPS (33c), consensus (35c)
Premium
The Fly
Sagimet Biosciences reports Q1 EPS (33c), consensus (35c)
4M ago
Sagimet Biosciences price target raised to $49 from $28 at Canaccord
Premium
The Fly
Sagimet Biosciences price target raised to $49 from $28 at Canaccord
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100